Coherus Oncology Inc

Avatud

SektorTervishoid

1.42 -2.07

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.42

Max

1.45

Põhinäitajad

By Trading Economics

Sissetulek

-279M

-38M

Müük

-438K

12M

P/E

Sektori keskmine

3.509

50.958

Aktsiakasum

-0.25

Kasumimarginaal

-308.197

Töötajad

145

EBITDA

9.3M

-34M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+468.97% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

6. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-31M

228M

Eelmine avamishind

3.49

Eelmine sulgemishind

1.42

Uudiste sentiment

By Acuity

50%

50%

137 / 342 Pingereas Healthcare

Coherus Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. juuni 2026, 23:31 UTC

News
Social Media

Comcast shares are higher in after-market trading amid reports of a potential expansion into video games and plans for AI-focused data centers.

29. juuni 2026, 23:26 UTC

Social Media
News

Micron Technology shares are lower after hours amid mixed sentiment and legal challenges over alleged memory chip production manipulation, despite revenue rising to $41.5 billion.

29. juuni 2026, 23:16 UTC

News

O'Reilly Automotive Inc shares are lower in after-market hours, following a slight decline since Monday's close amid a ranking rise in the S&P 500.

29. juuni 2026, 23:11 UTC

News
Correlated Moves

The GBP/HKD is higher today, reaching the upper end of its daily range amid market volatility from renewed U.S.-Iran hostilities ahead of talks in Doha.

29. juuni 2026, 23:06 UTC

News
ETF Constituents

Investor caution persists amid U.S.-Iran tensions, with the Vanguard Growth ETF showing little change in after-market trading. Microsoft leads contributors with a 0.85% return.

29. juuni 2026, 23:06 UTC

News

Regeneron Pharmaceuticals will join the FDA's PreCheck Pilot Program to enhance domestic drug manufacturing. Shares are trading lower in after-market hours.

29. juuni 2026, 23:06 UTC

News

U.S. West Texas Intermediate futures rose to $70.51 per barrel after a U.S.-Iran agreement eased tensions, supporting United States Oil Fund LP in after-market trading.

29. juuni 2026, 23:06 UTC

News

Piper Sandler initiated coverage of PayPal with a Neutral rating and a price target of $42.00. Shares were roughly flat in after-market hours.

29. juuni 2026, 23:02 UTC

News
ETF Constituents
Macro News
Correlated Moves

The Dow Jones Industrial Average closed above 52,000, driven by a rebound in technology stocks. The Vanguard Information Technology ETF showed little change in after-market hours.

29. juuni 2026, 20:07 UTC

News

The USD/THB is lower as optimism grows over U.S.-Iran talks after military exchanges. The asset remains above its 20-day moving average.

29. juuni 2026, 20:07 UTC

News
Correlated Moves

Ethereum is trading higher, supported by easing Middle East tensions and Bitmine's acquisition of 27,084 ETH, raising its total holdings to 5.7 million ETH.

29. juuni 2026, 20:07 UTC

Correlated Moves
Social Media
News
ETF Constituents

Positive sentiment for the SPDR Dow Jones Industrial Average ETF Trust follows a halt in U.S.-Iran military actions, easing geopolitical tensions and supporting stock futures.

29. juuni 2026, 20:07 UTC

Social Media
News

Intel shares are higher as Cantor Fitzgerald raises its price target to $150, indicating a recovery from early session lows.

29. juuni 2026, 20:07 UTC

News

Positive economic indicators and easing U.S.-Iran tensions boost the Nikkei 225 Index higher during after-market hours, with retail sales rising 5.3% year-on-year.

29. juuni 2026, 20:07 UTC

News

USD/ZAR is trading lower as optimism over U.S.-Iran talks eases energy supply concerns. This marks the third consecutive session of declines.

29. juuni 2026, 20:07 UTC

News
Correlated Moves

USD/PLN is lower today, influenced by a decline in the US Dollar Index and improved sentiment from U.S.-Iran relations.

29. juuni 2026, 20:07 UTC

News
Correlated Moves

Gold prices are lower today amid renewed U.S.-Iran tensions and potential Federal Reserve interest rate hikes. Crude oil's rise may diminish gold's safe-haven appeal.

29. juuni 2026, 20:07 UTC

Social Media
Correlated Moves
News

Trading lower amid a declining US Dollar Index; JPMorgan's blockchain impact.

29. juuni 2026, 20:07 UTC

News
Correlated Moves

USD/DKK is trading lower as the US Dollar Index declines. Renewed optimism over U.S.-Iran relations is also influencing market sentiment.

29. juuni 2026, 20:07 UTC

Correlated Moves
News

USD/CZK declines amid a falling US Dollar Index, reflecting volatility in today's session. The pair remains above its 20-day moving average.

29. juuni 2026, 20:06 UTC

News
Correlated Moves

Microchip Technology Inc is rising amid positive momentum in the semiconductor sector, supported by strength in the broader market and a favorable analyst consensus.

29. juuni 2026, 20:06 UTC

Correlated Moves
News

Gold prices are lower today amid renewed U.S.-Iran tensions and concerns over potential Federal Reserve interest rate hikes. Crude oil prices have surged as well.

29. juuni 2026, 20:06 UTC

Correlated Moves
News

USD/NOK is trading lower amid optimism over U.S.-Iran relations, despite remaining above its 20-day moving average. The US Dollar Index has also declined.

29. juuni 2026, 20:04 UTC

ETF Constituents
Correlated Moves
Social Media
News

SPDR S&P 500 ETF Trust advances as U.S. and Iran agree to halt military strikes, boosting market sentiment ahead of a diplomatic summit in Doha.

29. juuni 2026, 20:04 UTC

ETF Constituents
Social Media
News
Correlated Moves

Invesco QQQ Trust rises as U.S.-Iran tensions ease, boosting market sentiment. Strong performance from Amazon and Tesla supports the ETF's advance since Friday.

29. juuni 2026, 20:03 UTC

Social Media
News

Tesla Inc. shares are higher today amid positive delivery forecasts and the closure of an NHTSA investigation into power steering issues.

29. juuni 2026, 20:03 UTC

News
Correlated Moves

Alphabet Inc shares are higher today, supported by increased call volume and a favorable Supreme Court ruling easing regulatory concerns for tech companies.

29. juuni 2026, 20:03 UTC

News
Correlated Moves
Social Media
ETF Constituents

The Communication Services Select Sector SPDR Fund is gaining today, driven by strong performances from GOOGL and META amid a broader tech rally.

29. juuni 2026, 20:03 UTC

Social Media
News

GameStop is pursuing a $56 billion bid for eBay, despite rejection. eBay shares are trading higher amid acquisition discussions and technical platform issues.

29. juuni 2026, 20:03 UTC

Correlated Moves
Social Media
News

Amazon.com Inc. is advancing, supported by a market rally and a new partnership with Park Ha Biological to enhance personal care product offerings.

Võrdlus sarnastega

Hinnamuutus

Coherus Oncology Inc Prognoos

Hinnasiht

By TipRanks

468.97% tõus

12 kuu keskmine prognoos

Keskmine 8.25 USD  468.97%

Kõrge 12 USD

Madal 4 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Coherus Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

5

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

137 / 342 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
help-icon Live chat